Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect – a glimpse to the future. (3rd July 2018)

• Record Type: Journal Article
• Authors: Karamouzis, Michalis V.; Papavassiliou, Athanasios G.
• Is Part Of: Expert opinion on investigational drugs. Volume 27:Number 7(2018)
• Page Start: 569
• Page End: 572
• Publication Date: 2018-07-03
• Subjects: Immunotherapy -- cancer -- PD-1 -- ckeckpoint inhibitors -- immunotherapy combinations; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2018.1494724
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: In the last years, a remarkable progress has been made in the clinical application of novel immunotherapy agents, the so called 'checkpoint inhibitors, ' that has revolutionized the treatment of many malignant tumors. Their design has been based on the immune-mediated mechanisms of antitumor activity circle, such as antigen release and presentation, activation and trafficking of T-cells into tumors, depletion of immunosuppression, and immunogenic cell death. Various combinations of checkpoint inhibitors are being designed and/or tested, such as double checkpoint blockade, combination with chemotherapy, radiotherapy, molecularly targeted agents, and other immune-directed strategies.